Free Trial

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

$53.67
+0.86 (+1.63%)
(As of 07/12/2024 ET)

Crinetics Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$64.08
19.40% Upside
High Forecast$97.00
Average Forecast$64.08
Low Forecast$35.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$64.08$62.50$54.17$45.50
Forecasted Upside19.40% Upside50.09% Upside46.83% Upside148.96% Upside
Get Crinetics Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

CRNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CRNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Crinetics Pharmaceuticals Stock vs. The Competition

TypeCrinetics PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside19.40% Upside994.16% Upside9.19% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/9/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$47.00 ➝ $54.00+15.16%
7/2/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$97.00 ➝ $97.00+110.92%
6/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+38.03%
6/4/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$80.00 ➝ $80.00+72.86%
6/4/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$55.00 ➝ $74.00+59.90%
5/23/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$52.00 ➝ $62.00+27.78%
5/23/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$50.00 ➝ $70.00+41.84%
5/14/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$65.00+35.61%
3/20/2024Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$52.00 ➝ $56.00+23.95%
3/6/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$68.00+58.40%
12/21/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$35.00+1.48%
9/11/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$41.00 ➝ $48.00+200.56%
3/27/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Jubinville
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:35 AM ET.

CRNX Forecast - Frequently Asked Questions

What is Crinetics Pharmaceuticals' forecast for 2024?

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Crinetics Pharmaceuticals is $64.08, with a high forecast of $97.00 and a low forecast of $35.00.

Should I buy or sell Crinetics Pharmaceuticals stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRNX shares.

Does Crinetics Pharmaceuticals's stock price have much upside?

According to analysts, Crinetics Pharmaceuticals's stock has a predicted upside of 49.82% based on their 12-month stock forecasts.

What analysts cover Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, and Robert W. Baird in the past 90 days.

Do Wall Street analysts like Crinetics Pharmaceuticals more than its competitors?

Analysts like Crinetics Pharmaceuticals more than other "medical" companies. The consensus rating score for Crinetics Pharmaceuticals is 2.92 while the average consensus rating score for "medical" companies is 2.71. Learn more on how CRNX compares to other companies.


This page (NASDAQ:CRNX) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners